DrugBiological
Urelumab clinical trials
Also written BMS-663513.
- studies test it
- 16
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 5
Bristol-Myers Squibb (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Chicago (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Nivolumab (3) · Rituximab (2) · Cyclophosphamide (1) · HuMax-IL8 (1) · Immune Checkpoint Inhibitors (1) · Cabiralizumab (1) · Lirilumab (1) · Cetuximab (1)
Studies
Open first, then newest update. How each study uses urelumab is read from its arms, and is right about nine times in ten.
Testing it · 16
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02451982Written as Urelumab
- Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)CompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02658981Written as Anti-CD137
- Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerCompletedPhase 1University of ChicagoNCT03431948Written as Urelumab
- An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's LymphomaTerminatedPhase 1/2Bristol-Myers SquibbNCT02253992Written as Urelumab
- Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsCompletedPhase 1Bristol-Myers SquibbNCT02534506Written as Urelumab
- Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid TumorsStatus unknownPhase 1/2Clinica Universidad de Navarra, Universidad de NavarraNCT03792724Written as Urelumab + Nivolumab
- A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedPhase 1Bristol-Myers SquibbNCT02252263Written as Urelumab
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck CancerCompletedPhase 1Bristol-Myers SquibbNCT02110082Written as Urelumab
- Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaCompletedPhase 1Bristol-Myers SquibbNCT01471210Written as Urelumab (BMS-663513)
- Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins LymphomaCompletedPhase 1Bristol-Myers SquibbNCT01775631Written as Urelumab
- Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsWithdrawnPhase 2M.D. Anderson Cancer CenterNCT02420938Written as Urelumab
- Phase II, 2nd Line Melanoma - RAND MonotherapyCompletedPhase 2Bristol-Myers SquibbNCT00612664Written as Anti-CD137 (4-1BB) (BMS-663513)
- Study of BMS-663513 in Patients With Advanced CancerTerminatedPhase 1/2Bristol-Myers SquibbNCT00309023Written as BMS-663513
- Combination of Anti-CD137 & Ipilimumab in Patients With MelanomaWithdrawnPhase 1Bristol-Myers SquibbNCT00803374Written as AntiCD137
- A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid MalignanciesTerminatedPhase 1Bristol-Myers SquibbNCT00351325Written as BMS-663513
- A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)TerminatedPhase 1Bristol-Myers SquibbNCT00461110Written as BMS-663513
Codes
What other systems call urelumab · ClinicalTrials.gg INT000723
- MeSH (NLM) C000620833urelumabOne source NLM
- UNII (FDA) 230902QLLCURELUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7900382UrelumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62449UrelumabOne source FDA
- DrugBank DB12077One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000620833 | urelumab | One source NLM |
| UNII (FDA) | 230902QLLC | URELUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7900382 | Urelumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62449 | Urelumab | One source FDA |
| DrugBank | DB12077 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.